ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.735,25
0,28%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08347
0,09%
Bitcoin
69.722,29
0,90%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. GeoVax Labs Inc (GOVXW)

  7. GeoVax Labs Inc (GOVXW) News

GOVXW GeoVax Labs Inc

0,04
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
GeoVax Labs Inc GOVXW NASDAQ Equity Warrant
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 0,04 10:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,04
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
21.5.202423:23EDGAR2Form 8-K - Current report
21.5.202418:32EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15.5.202422:03EDGAR2Form 8-K - Current report
14.5.202423:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.5.202423:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.5.202423:08EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.5.202423:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.5.202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04.4.202418:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
28.3.202414:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
12.3.202414:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
06.3.202415:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
29.2.202422:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
22.2.202415:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
19.2.202415:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
13.2.202415:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
06.2.202415:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
29.1.202415:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
08.1.202415:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
04.1.202415:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
03.1.202415:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
27.12.202315:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
19.12.202315:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
30.11.202322:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
29.11.202315:00GLOBEGeoVax to Participate in Upcoming December Investor Events
28.11.202315:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
14.11.202315:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
08.11.202322:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
31.10.202314:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
30.10.202314:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
25.10.202315:00GLOBEGeoVax to Participate in Upcoming November Investor and..
24.10.202315:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
09.10.202315:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
05.10.202315:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27.9.202315:00GLOBEGeoVax to Participate in Upcoming October Investor and..
26.9.202315:00GLOBEGeoVax Secures Multi-Product License for ProBioGen's..
20.9.202315:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Data Presented at..
19.9.202315:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent..
12.9.202315:00GLOBEGeoVax Presents Corporate Update at the H.C. Wainwright 25th..
11.9.202315:00GLOBEGeoVax Completes Enrollment of Phase 2 Trial for..
31.8.202315:00GLOBEGeoVax to Present at the H.C. Wainwright 25th Annual Global..
28.8.202315:00GLOBEGeoVax Receives Notice of Allowance for Malaria Vaccine..
10.8.202315:00GLOBEGeoVax Announces First Patients Vaccinated in Phase 2..
09.8.202322:00GLOBEGeoVax Reports 2023 Second Quarter Financial Results and..
26.7.202315:00GLOBEGeoVax to Report Second Quarter 2023 Financial Results and..
24.7.202315:00GLOBEGeoVax Announces Issuance of Ebola Vaccine Patent
20.7.202315:00GLOBEGeoVax Announces Initiation of Phase 2 Clinical Trial of..
10.7.202315:00GLOBEGeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS..
28.6.202315:00GLOBEGeoVax Announces Gedeptin® Presentation at the AACR-AHNS..
27.6.202316:15GLOBEGeoVax Universal Coronavirus Vaccine Design & Development..

Kürzlich von Ihnen besucht

NASDAQ
GOVXW
GeoVax Labs
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten